60 likes | 69 Views
Hepatitis is a viral infection that affects the liver and can lead to inflammation, liver damage, and other complications. There are several types of hepatitis viruses, including hepatitis A, B, C, D, and E. The treatment of hepatitis depends on the specific virus causing the infection.
E N D
Global Hepatitis Drugs Market Market Size (2023) US$ 21,148.3 MN CAGR (2023–2030) 3.2% Market Size (2030) US$ 27,180.1BN
Segmentation (Scope) By Disease By Drugs Class • Hepatitis B • Interferon Alphas • Hepatitis C • HIV NRTIs • Nucleotide Polymerase / • NS5A Inhibitor Combinations • Others • Hepatitis C Protease / • NS5A Inhibitor Combinations • NS5A Inhibitors • Nucleotide Polymerase Inhibitors • Nucleoside Analogue Antivirals • Thrombopoiesis Stimulating Agents © Coherent Market Insights. All Rights Reserved
Key Facts • Direct-acting antiviral (DAA) therapies have transformed the treatment of hepatitis C virus (HCV) infections. • DAAs offer high cure rates and fewer side effects compared to older treatment options. • The rising prevalence of hepatitis infections worldwide is driving the growth of the hepatitis drugs market. • The development of vaccines for hepatitis B virus (HBV) and innovative therapies for hepatitis D virus (HDV) is an area of focus in the market. © Coherent Market Insights. All Rights Reserved
Market Purview • The market includes a range of medications, including antiviral drugs, immunomodulators, and combination therapies. • Hepatitis drugs aim to reduce viral replication, suppress the virus, and prevent liver damage or cirrhosis. • The market is driven by factors such as the increasing prevalence of hepatitis infections globally, growing awareness about the availability of effective treatments, and advancements in drug development. © Coherent Market Insights. All Rights Reserved
Few Leading Companies Merck & Co. Inc. Gilead Sciences Inc. AbbVie Inc. Bristol Myers Squibb Company © Coherent Market Insights. All Rights Reserved